|Systematic (IUPAC) name|
|Molar mass||225.222 g/mol|
|(what is this?)|
CGP-35348 was ineffective up to 100 μM to antagonize the inhibitory release of GABA elicited by baclofen, doing it selective as GABAB heteroreceptor antagonist.  Moreover, CGP35348 was about threefold less potent to antagonize GHB and GBL than baclofen and SKF97541. 
- Carter LP, Chen W, Coop A, Koek W, France CP (May 2006). "Discriminative stimulus effects of GHB and GABA(B) agonists are differentially attenuated by CGP35348". European Journal of Pharmacology. 538 (1-3): 85–93. doi:10.1016/j.ejphar.2006.03.039. PMID 16647701.
- Nasrallah FA, Griffin JL, Balcar VJ, Rae C (August 2007). "Understanding your inhibitions: modulation of brain cortical metabolism by GABA(B) receptors". Journal of Cerebral Blood Flow and Metabolism. 27 (8): 1510–20. doi:10.1038/sj.jcbfm.9600453. PMID 17293844.
- Koek W, Mercer SL, Coop A, France CP (September 2009). "Behavioral effects of gamma-hydroxybutyrate, its precursor gamma-butyrolactone, and GABA(B) receptor agonists: time course and differential antagonism by the GABA(B) receptor antagonist 3-aminopropyl(diethoxymethyl)phosphinic acid (CGP35348)". The Journal of Pharmacology and Experimental Therapeutics. 330 (3): 876–83. doi:10.1124/jpet.109.151845. PMC . PMID 19564487.
- Maurizio Raiteri. "Functional Pharmacology in Human Brain". doi:10.1124/pr.58.2.5.
- Koek W1, Mercer SL, Coop A. "Cataleptic effects of gamma-hydroxybutyrate (GHB), its precursor gamma-butyrolactone (GBL), and GABAB receptor agonists in mice: differential antagonism by the GABAB receptor antagonist CGP35348.".
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|